What is Biocept?
Biocept, Inc. is a biotechnology company focused on the development and commercialization of molecular diagnostic assays. These assays provide physicians with actionable clinical information for the treatment and monitoring of cancer patients. The company's portfolio includes blood-based liquid biopsy assays and the specialized CNSide cerebrospinal fluid assay, designed to detect central nervous system metastasis. Biocept leverages its patented Target Selector technology for capturing and analyzing cerebrospinal fluid tumor cells, utilizing advanced molecular diagnostic capabilities. Additionally, the company has extended its expertise to offer nationwide COVID-19 RT-PCR testing, contributing to public health initiatives.
How much funding has Biocept raised?
Biocept has raised a total of $96.8M across 12 funding rounds:
Series C
$3.6M
Series D
$2.3M
Debt
$1.2M
Stock Offering
$19M
Share Placement
$9.3M
Stock Offering
$13.3M
Stock Offering
$10M
Multiple Rounds
$26.1M
Series C (2010): $3.6M, investors not publicly disclosed
Series D (2010): $2.3M, investors not publicly disclosed
Debt (2011): $1.2M, investors not publicly disclosed
Stock Issuance/Offering (2014): $19M, investors not publicly disclosed
Share Placement (2017): $9.3M led by Chardan Capital and ROTH Capital Partners
Stock Issuance/Offering (2018): $13.3M, investors not publicly disclosed
Stock Issuance/Offering (2019): $10M, investors not publicly disclosed
Share Placement (2020): $9.2M, investors not publicly disclosed
Share Placement (2020): $6.6M, investors not publicly disclosed
Share Placement (2020): $10.3M, investors not publicly disclosed
Key Investors in Biocept
Needham Capital Partners
Needham Capital Partners is an investment banking and asset management firm specializing in growth companies. With a focus on public and private financings, mergers, and acquisitions, they provide strategic advisory services to their clients.
Chardan Capital
Chardan Capital is an investment firm that provides capital and strategic support to companies, likely focusing on the healthcare and technology sectors.
ROTH Capital Partners
ROTH Capital Partners is a full-service investment banking firm known for its expertise in emerging growth companies, particularly within the healthcare and technology industries.
What's next for Biocept?
The substantial enterprise-level funding indicates Biocept is likely in a growth or scaling phase, potentially focusing on expanding its assay portfolio, enhancing its diagnostic platform, and increasing market penetration. The strategic nature of recent investments suggests a focus on strengthening its competitive position and advancing its pipeline of cancer diagnostic tools. Future developments may involve further clinical validation, regulatory approvals, and strategic partnerships to broaden access to its innovative diagnostic solutions.
See full Biocept company page
